In cardiac wound healing following myocardial infarction (MI), relatively inactive 47 resident cardiac fibroblasts phenoconvert to hypersynthetic/secretory myofibroblasts that 48 produce large quantities of extracellular matrix (ECM) and fibrillar collagen proteins. Our lab 49 and others have identified TGFβ 1 as being a persistent stimulus in the chronic and inappropriate 50 wound healing phase that is marked by hypertrophic scarring and eventual stiffening of the entire 51 myocardium, ultimately leading to the pathogenesis of heart failure following MI. Ski is a potent 52 negative regulator of TGFβ/Smad signaling with known anti-fibrotic effects. Conversely, 53
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sequence CAGACA) within the promoter regions of TGFβ-regulated genes (6, 12). There, Smad 114 complexes recruit transcriptional co-activators to induce transcription of target genes (20, 35) . 115
Ski has been identified as a potent inhibitor of TGFβ 1 /Smad signaling through the 116 disruption of Smad binding complexes bound to the promoters of TGFβ 1 -regulated genes (27, 117 32) . Our group has recently reported on the anti-fibrotic effects of Ski in the cardiac 118 myofibroblast such that ectopic expression of Ski repressed the synthesis of fibrillar collagens 119 and α-smooth muscle actin (α-SMA), and reduced cell contraction (11). Additionally, we found 120 that Ski co-localized with Smad2 when overexpressed, confirming previous reports that Ski 121 forms complexes with Smad proteins to repress TGFβ 1 -mediated gene transcription (11, 27, 32) . 122
It is unknown whether this Smad-dependent mode of repression extends to all genes regulated by 123
Ski. 124
In contrast to the anti-fibrotic properties of Ski, Scleraxis has been identified as a potent 125 pro-fibrotic agent through its regulation of the fibrillar collagen 1α1 and 1α2 genes (2, 14, 24) . 126
Scleraxis is a basic helix-loop-helix transcription factor that binds to the E-box consensus 127 sequence CANNTG (where N can be any nucleotide) (9, 30) . Recently, our group has published 128 that Scleraxis expression is induced in response to TGFβ 1 stimulation at both the mRNA and 129 protein levels in cardiac myofibroblasts (2, 14) . Additionally, ectopic expression of Smad3 in 130 primary cardiac myofibroblasts induced Scleraxis protein expression, whereas Smad7 expression 131 nearly abolished Scleraxis expression (2). Furthermore, we found that Scleraxis was a critical 132 regulator of the collagen 1α2 gene that worked synergistically with Smad proteins to induce gene 133 transcription (2). 134
Despite several publications that have described a link between TGFβ stimulation and 135
Scleraxis protein expression (3, 4, 14) , there are no published studies that address the molecular 136 6 mechanisms that regulate this relationship. In this study, we provide evidence to support a novel 137
Smad-independent molecular mechanism by which TGFβ 1 induces Scleraxis expression. For the 138 first time, we provide data revealing the existence of a TGFβ 1 -driven MAPK-dependent pathway 139 that modulates Scleraxis expression and thatthis Smad-independent pathway is functional in the 140 primary cardiac myofibroblast. We also show that the anti-fibrotic action(s) of Ski extend to the 141 tight transcriptional and translational repression of Scleraxis mRNA and protein expression. 142
Finally, we provide evidence to demonstrate that the MAPK pathway plays a significant role in 143 the regulation of Scleraxis through a p42/44 (Erk1/2) -dependent pathway. Thus, we provide data 144 that supports the hypothesis that TGFβ 1 drives a novel Smad-independent signaling cascade that 145 may play an important role in regulating the fibrotic response in activated cardiac myofibroblasts 146 following cardiac injury. 147
Materials and Methods 148
Cell Culture 149
Primary rat cardiac myofibroblasts were isolated as previously described (18). Briefly, 150 adult male Sprague-Dawley rats (200-250g) were anesthetized with a ketamine:xylazine (1:1) 151 cocktail. Upon loss of reflex activity, heparin was administered via the femoral or tail vein, the 152 chest cavity opened, and hearts removed. Hearts were hung from a cannula and perfused with 153 DMEM-F12 supplemented with 100 U/mL penicillin, 100 U/mL streptomycin, 1.2 g/L sodium 154 bicarbonate, and 1 μM ascorbic acid, followed by SMEM (to stop contractions), and 0.1% 155 collagenase type II/SMEM solution to digest the tissue. Following digestion, hearts were broken 156 apart and large tissue pieces allowed to settle. The supernatant was then removed and subjected 157 to centrifugation at 2000 rpm for 5min. Cell pellets were re-suspended in DMEM-F12 with 10% 158 fetal bovine serum (FBS) and 5 ng of pRL to serve as a transfection control. 100-350 ng of empty expression vector 186 (pcDNA3, pCMV-Tag2b) was used to bring the final DNA mass to 500 ng. Cells were harvested 187 24 hours later for luciferase assay. Luciferase activity for each sample was determined in 188 triplicate using the Dual Luciferase Reporter Assay System (Promega) with a GloMAX 189 luminometer (Promega). 190
Western Blot Analysis 191
P1 cardiac myofibroblasts were infected with Ad-LacZ (50 MOI) and MOI) at the time of plating. Twenty-four hours later, cells were harvested in RIPA lysis buffer 193 containing protease (Sigma) and phosphatase (10 mM NaF, 1 mM Na 3 VO 4 , 1 mM EGTA) 194 inhibitors. Cells were incubated for 60 minutes on ice and sonicated 3 x 10 seconds. Cell lysates 195 were incubated on ice for 2-3 minutes between each pulse. Cellular debris was removed from the 196 samples by centrifugation at 16000 x g for 20 minutes at 4 o C. Supernatants were placed into 197 fresh tubes and protein concentrations determined using the BCA method on an iMark™ 198 microplate absorbance reader (Bio-Rad Laboratories) . 199
Ten to 20 μg of protein was subjected to 10-12% SDS-PAGE. Protein was transferred to 200 0.45 μm PVDF membrane and blocked in 5% skim milk in TBS-T for 60 minutes at room 201 temperature. Blots were washed in TBS-T and incubated with primary antibody (Ski, QED; 202 GAPDH, phospho-p42/44, and p42/44 Cell Signaling; Scleraxis (M.P.C. lab) (2, 14)) in either 203 5% BSA in TBS-T or 3% skim milk in TBS-T overnight at 4 o C with gentle agitation. The next 204 day, blots were washed in TBS-T and incubated in secondary antibody (Goat-Anti-Rabbit) 
Electrophoretic Mobility Shift Assays 232
Biotinylated and non-labelled probes encompassing conserved SBE in the 233 human/mouse/rat Scleraxis promoter ( Figure 1B Biotechnology) was added to each tube and incubated for 2 hours at room temperature with 272 rotation. Next, 500μL of IP wash buffer (25mM Tris, 150mM NaCl, ph7.2) was added to each 273 sample and beads pelleted at 2500 xg for 2 minutes at room temperature. The supernatant was 274 removed and the beads washed 3 times in IP wash buffer and once in DDW in 500uL of solution 275
and 5 minutes of rotation at room temperature. Beads were pelleted at 2500 xg as before. After 276 the final wash, the protein complexes were removed from the beads under denaturing conditions 277 with 3x loading buffer (187.5mM Tris-HCl pH 6.8, 6% SDS (w/v), 30% glycerol, 0.03% phenol 278 red, 1.25M dithiothreitol (DTT) and heated at 95 o C for 5 minutes in a heat block. Samples were 279 centrifuged at 14000 xg for 1 minute and the supernatant loaded directly onto a SDS 280 polyacrylamide gel and assayed for protein detection as described above. 281
Statistics 282
Data are presented as mean ± SEM. Comparisons between two groups was done using a 283
Students t-test. Grouped data was analysed by one-way ANOVA with a Student-Newman-Keuls 284 post-hoc test as required using Graph Pad Prism 5. A P-value < 0.05 was considered statistically 285
significant. 286
Results 287
Scleraxis expression is reduced by Ski 288
Previous studies have demonstrated that Scleraxis expression increases following TGFβ 289 treatment in numerous animal models and tissue types (2, 3, 5, 14, 26, 29) . To confirm these 290 results in our model, we stimulated P1 cardiac myofibroblasts with 10 ng/mL TGFβ 1 for 24 291 hours. As in previous reports, we observed a 2.5-3 fold induction (P < 0.05) of Scleraxis protein 292 expression following TGFβ 1 stimulation ( Figure 2 ). As Scleraxis has been well documented by 293 us and others as being regulated through TGFβ, we sought to confirm this notion by using an 294 inhibitor of TGFβ 1 /Smad signaling. Ski has been identified as a potent regulator of TGFβ 1 295 signaling by disrupting R-Smad/Co-Smad complexes at the promoter region of TGFβ 1 -regulated 296 genes, and by recruiting transcriptional co-repressors to repress gene transcription (1, 32). Our 297 group has recently shown that ectopic expression of Ski in P1 cardiac myofibroblasts is able to 298 reduce the expression of pro-fibrotic proteins including collagen I and α-smooth muscle actin 299 (11). As Scleraxis exhibits pro-fibrotic properties (2, 14) and Ski anti-fibrotic properties, we 300 sought to determine whether Ski expression plays a role in Scleraxis expression. We over-301 expressed Ski in primary cardiac myofibroblasts for 24 hours and analyzed cell lysates for 302 Scleraxis protein and mRNA levels ( Figure 3 ). As shown in Figure 3B , ectopic expression of Ski 303 was able to reduce Scleraxis protein levels by 80-90% as compared to LacZ and non-transfected 304 14 controls (P < 0.05). Furthermore, using qRT-PCR we observed a 50-60% reduction in Scleraxis 305 mRNA levels as compared to LacZ and non-transfected controls after 24 hours of Ski expression 306 ( Figure 3C ; P < 0.05). These results suggest that Ski may play a key role in the negative 307 regulation of Scleraxis regulation via an as of yet unknown mechanism. 308
TGFβ 1 induces transcription of Scleraxis by a Smad-independent mechanism 309
While previous studies have provided evidence that Scleraxis expression (protein and 310 mRNA) levels increase in response to TGFβ and ectopic Smad3 (2-4), there is no evidence that 311 addresses the direct mechanism(s) that underlie Scleraxis expression. Thus, we questioned 312 whether activation of Scleraxis transcription is governed by TGFβ 1 through Smad-dependent 313 TGFβ 1 /Smad signaling. In silico analysis of the human, mouse, and rat Scleraxis promoter 314 regions shows that there two highly-conserved, though putative, SBE in the Scleraxis promoter 315 region that may constitute binding sites for Smad proteins ( Figure 1B) . In order to test whether 316 TGFβ 1 is capable of activating the Scleraxis promoter, we performed luciferase assays in NIH-317 3T3 cells with and without increasing doses of TGFβ 1 . Following TGFβ 1 treatment, there was an 318 increase in luciferase expression that peaked with 5 ng/mL TGFβ 1 ( Figure 4A ). 319
We then addressed whether TGFβ 1 's activation of the Scleraxis promoter was due to 320 Smad-dependent TGFβ 1 /Smad signaling or through an alternative, Smad-independent pathway. 321
Thus, we performed luciferase assays with transfection of Smad2 and Smad3 expression vectors 322 ( Figure 4B and 4C) . Should the 1.5 kb hScx promoter be controlled through Smad2 and/or 323 Smad3, we ought to be able to measure a change in luciferase activity. Despite the dose 324 dependent activation of the hScx promoter by TGFβ 1 , increased expression of either Smad 325 proteins were not associated with altered luciferase activity when compared to empty vector 326 15 controls (Figure 4B, 4C; P > 0.05). This data suggest that Scleraxis expression may be regulated 327 through a Smad-independent TGFβ 1 signaling pathways. 328
Smad proteins do not bind the promoter region of human Scleraxis 329
To determine whether Smad proteins bound to, but did not activate transcription of hScx, 330
we conducted EMSA assays to confirm our luciferase findings. 500-1000 ng of nuclear protein 331 lysate from untreated Cos7 (data not shown) or P1 cardiac myofibroblasts was subjected to 332 binding assays as described above. When biotin-labelled oligonucleotides containing both SBEs 333 found in the hScx promoter were incubated with Cos7 and P1 myofibroblast nuclear lysates a 334 shift was observed and this shift was abolished by pre-incubation with a 500-fold molar excess 335 of unlabelled "cold" probe ( Figure 5 ). However, there was no supershift detected with the 336 addition of antibodies against either Smad2 or Smad3. Additionally, incubation with a mutant 337 "cold" probe was able to compete for binding with the labelled wild-type probes ( Figure 5) . 338
These results led us to investigate means by which TGFβ 1 may regulate Scleraxis expression 339 through Smad-independent mechanisms. 340
MAPK signaling alters Scleraxis expression 341
While traditional Smad-dependent TGFβ 1 signaling appears not to be a key regulatory 342 mechanism of Scleraxis expression, we sought to determine whether Smad-independent 343
TGFβ 1 /MAPK signaling may play a role in regulating Scleraxis levels. Primary P1 cardiac 344 myofibroblasts were pretreated with 10 μM U0126 (a MEK1/2 inhibitor) or DMSO (vehicle) for 345 2 hours followed by TGFβ 1 treatment for an additional 1 or 24 hours. TGFβ 1 treatment of P1 346 cardiac myofibroblasts significantly increased the amount of phospho-p42:44/total p42:44 levels 347 after 1 hour of stimulation, but not after 24 hours (Figures 6A, 7A ). As expected, U0126 348 treatment resulted in a significant reduction in phospho-p42:44/total p42:44 levels ( Figure 6A , 349 16 7A; P < 0.05) after both 1 and 24 hours that could not be rescued with TGFβ 1 stimulation. 350
Moreover, TGFβ 1 treatment resulted in a significant increase in Scleraxis protein levels in the 351 vehicle-treated as compared to U0126-treated and untreated controls ( Figure 7B ). However, pre-352 treatment of P1 cardiac myofibroblasts with U0126 prevented the TGFβ 1 -induced increase in 353
Scleraxis protein expression after 24 hours ( Figure 7B ). In the absence of TGFβ 1 , U0126 still 354 exerted a significant effect on p42/44 protein expression ( Figure 7C ) with no significant effect on 355 endogenous Scleraxis protein levels ( Figure 7D ). These data suggest that the Smad-independent 356
TGFβ 1 /MAPK may be an important factor regulating Scleraxis protein expression. 357
Ski interacts with c-jun in primary cardiac myofibroblasts 358
As we have now demonstrated a role for MAPK signaling in the regulation of Scleraxis 359 expression, we carried out an investigation as to whether Ski may be involved in this process. 360
We conducted immunoprecipitation assays where we used c-Jun to bind and pull down Ski. As 361 demonstrated in Figure 8A , Ski protein was precipitated along with c-jun only in those cells 362 which Ski was overexpressed, suggesting an important role for Ski in regulation of Smad-363 independent MAPK-signaling of scleraxis. 364
Discussion 365
Maladaptive remodeling of the myocardium following cardiac injury is considered to be a 366 primary cause for the development of overt heart failure with ensuing mortality. Activation of 367 resident cardiac fibroblasts into hypersynthetic/secretory myofibroblasts is now generally 368 regarded as the seminal event in the up-regulation and enhanced deposition of fibrillar collagens 369 and ECM which, in acute phases, assists in cardiac wound healing, but in chronic phases, 370 ultimately culminates in cardiac dysfunction due to global stiffening of the non-infarcted 371 myocardium remote to the infarct scar (8, 34, 40, 42, 43, 45) In the current study, we chose to explore the profibrotic effects of TGFβ 1 over TGFβ 2 and 389 TGFβ 3 as the former has been extensively described in the literature as a driving force behind the 390 remodeling process in the heart. A recent study by Khan et al. 2012 analyzed serum and tissue 391 levels of TGFβ 1 in healthy and post-MI myocardium(23). Active (free) serum levels of TGFβ 1 392 were low (2ng/mL) compared to total (free + latent) levels which reached as high as 136 ng/mL. 393
Alternatively, tissue active levels of TGFβ 1 in the healthy myocardium were relatively low (<1.0 394 ng/mL) while total levels were been estimated at ~ 2.0 ng/mL(23). Following MI, active levels of 395 TGFβ 1 were increased to levels greater than 3 ng/mL while total levels ranged ~ 7 ng/mL. Thus, 396 the selected range of TGFβ 1 concentrations that we utilized for our luciferase assays mimicked 397 that of healthy and diseased myocardial levels. Herein we have demonstrated that treatment of 398 myofibroblasts with TGFβ 1 resulted in 2-3 fold induction of Scleraxis 24 hours after stimulation 399 (Figure 2 ). This data is in agreement with previously published reports which found that 400 stimulation of a variety of cell types with TGFβ1, 2, or 3 was capable of inducing Scleraxis 401 expression to a similar degree (2-4, 14, 24, 26). However, none of these studies addressed the 402 molecular mechanisms which underpin this expression profile. Hence, we cloned 1.5 kb of the 403 human Scleraxis promoter in a luciferase reporter to test whether Smad proteins could directly 404 influence Scleraxis gene expression. This region contains 2 highly conserved, though putative, 405 SBEs ( Figure 1B) , to which Smad protein complexes may bind. Not surprisingly, increasing 406 doses of TGFβ 1 induced luciferase expression in a biphasic response pattern ( Figure 4A ). As 407 TGFβ 1 operates via receptor activation it is not uncommon to see biphasic responses past 408 saturation points of receptors by the free ligand. However we did notexpect to observe that co-409 transfection with Smad2 or Smad3 expression vectors were unable to stimulate reporter 410 expression ( Figure 4B, 4C ). This evidence indicates that, in this experimental system, wherein 411 we address promoter activation directly, R-Smad proteins do not appear to be direct mediators of 412 Scleraxis gene expression within this promoter region. Our conclusions differ from that of a 413 recent publication by Bagchi and Czubryt (2) who demonstrated that adenoviral over-expression 414 of Smad3 was sufficient to induce Scleraxis protein expression. We suggest that in their model, 415
Smad3 may promote the expression of an as yet undescribed positive regulator of Scleraxis, 416 which may account for the positive result for Scleraxis expression or alternatively, ay work at a 417 SBE outside of the 1.5kb promoter. It is also possible that we did not capture the functionally 418 active SBE within our reporter construct and Smad proteins may play a role through regulation 419 of enhancer elements located elsewhere in the genome. Taken together, our data thus far 420
indicates that an alternative TGFβ 1 -dependent signaling pathway may be responsible for 421
Scleraxis regulation in the cardiac myofibroblast through a Smad-independent mechanism. 422 TGFβ1 has the ability to signal down multiple Smad-independent pathways including 423 Rho/ROCK, PI3K/AKT, and p38/ERK/MAPK (1, 19, 21, 38 Figure 6 ) and this inhibitory effect was seen as far out as 24 hours after treatment (Figure 7) . 433 However, we saw normalization among untreated and TGFβ 1 + vehicle treated controls after 24 434 hours, indicating that the MAPK flux is short-lived and after 24 hours the signal has diminished 435 beyond detectable levels. In relation to Scleraxis, we saw no change in Scleraxis protein levels 436 amongst any of the treatment groups after just 1 hour of TGFβ1 stimulation ( Figure 6B ). After 437 24 hours however there was a 2-3 fold induction of Scleraxis protein expression with TGFβ 1 + 438 vehicle treatment which was partially rescued with U0126 pre-treatment although it did not reach 439 significance ( Figure 7B ). There was no effect on endogenous Scleraxis protein expression with 440 U0126 treatment alone despite attenuation of phospho-p42/44 ( Figure 7C and D) Scleraxis expression (3). While our current study and those conducted by Barnette et al. concur 448 on the ability of TGFβ to regulate Scleraxis expression, there are fundamental differences in the 449 approaches that were taken that are worthy of highlighting. We note that we stimulated primary 450 cardiac myofibroblasts with 10 ng/mL (~400pM) of TGFβ 1 for 24 hours in serum-free media, 451 whereas the study by Barnette et al. used TGFβ 1 drives a diverse array of cellular responses and has been described as a pluripotent 459 cytokine. Similarly, Ski is a protein which has been ascribed a complex subset of functions 460 including skeletal muscle growth, inhibition of fibrillar collagen synthesis in cardiac 461 myofibroblasts, as well as controlling fibroblast-to-myofibroblast phenoconversion (10, 11, 41) , 462 and is best described as a negative regulator of TGFβ 1 . In this report, we provide evidence for 463 potent negative regulation of Scleraxis expression by Ski. The mechanism of this downregulation 464
21 has yet to be fully determined. We have begun to elucidate this mechanism through 465 immunoprecipitation studies. We found that in those cells that overexpress exogenous Ski, we 466 were able to pull down Ski alongside c-jun, indicating that they are, at the very least, a part of a 467 protein complex. Our results correlate with those published by Pessah et al. in 2002, who 468 showed that Ski and c-Jun were able to interact with one another and turn off gene expression 469 (33). Our current results extend those presented by Pessah and colleagues in that we have shown 470 that the Ski:c-Jun protein interaction occurs in primary cells which are biologically relevant to 471 the pathobiology of cardiac matrix remodeling. We suggest that this Ski:c-Jun interactions may 472 play an important role in regulating Scleraxis expression as there is a putative AP1 transcription 473 factor binding site found within our cloned 1.5kb human Scleraxis promoter (Figure 1 ; see the 474 red oval). 475
As Scleraxis is a putative candidate as a cellular nexus in upregulating fibrillar collagen 476 expression, multiple pathways may be utilized by the cardiac myofibroblast to exert fine control 477 of this mechanism, including inhibition by Ski. In this regard, Ski may function as an effective 478 cellular "brake" to inhibit expression of Scleraxis. 479 This study represents the discovery of the p42/p44 path subsequent to TGFβ 1 signaling 480 providing a link to regulation of Scleraxis expression. While we found that Ski, a known TGFβ 1 481 repressor protein is a potent inhibitor of Scleraxis expression, we do not currently understand 482 whether this repression is also linked p42/p44 deactivation. Although we have generated 483 preliminary evidence to support the suggestion that Ski may exert a regulatory role in inhibiting 484 AP1 complexes through their association with one another, more work is required and this line 485 of experimentation extendsbeyond the scope of the current paper. 486
In summary, the current data provide support for a novel mechanism of Scleraxis 487 induction by TGFβ 1 in primary cardiac myofibroblasts, and novel evidence that Ski is a potent 488 negative regulator of Scleraxis. The induction of Scleraxis by TGFβ 1 occurs by a novel, Smad-489 independent mechanism (Figure 8) , apparently through the Smad-independent MAPK pathway 490 in the cardiac myofibroblast. Whether AP1 or other transcription factors downstream of the 491 MAPK pathway are responsible for this activation is yet to be determined. Our results provide 492 insight into both stimulation and repression of Scleraxis in primary cardiac myofibroblasts and 493 extend our knowledge of how this potent, pro-fibrotic protein is regulated in the myocardium. We would like to thank Natalie Landry for her critical assessment of various iterations of this 503 Table 1 . Scleraxis and GAPDH qRT-PCR primer pairs. *As previously published by Bagchi and 673 Czubryt (2) downregulation has yet to be determined. We suggest that as Scleraxis is a cellular nexus in 766 upregulating fibrillar collagen expression, and that multiple pathways may be utilized by the 767 cardiac myofibroblast to exert fine control of this mechanism. Finally, pluripotent Ski functions 768 as the effective cellular "brake" to inhibit expression (and likely function) of Scleraxis. 769
Putative SBEs: Proximal: Mm: AGTGCACATGGAAGGAGAGTCAGACAGGGTGTGGCCAGGCACTCAG -445 Hs: GCGCACATGGGAGGCAAAGACAGACAGGGTGCGGTCAGGCAGCAGG -490 Rn: AGTGCACATGGAAGGAGAGTCAGACAGGGTGTGGCCAGGCACTCAG -444 *** * * ** *********** ** ****** * Distal: Mm: GCCAAGGCTCTGGGCAGCCACAGACAGGGATGACCTCATCGCCTAT -1260 Hs: GCCAGGGCTCTGGGCAGCCACAGACAGGGATGACCTCATCACCCAC -1211 Rn: GCCAAGGCTCTGGGCAGCCACAGACAGGGATGACCTCATCGCCTAT -1297 **** *********************************** ** * A) B)
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